NCT06088498 App for Reducing Cravings to Smoke
| NCT ID | NCT06088498 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Condition | Smoking |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,600 participants |
| Start Date | 2024-06-11 |
| Primary Completion | 2027-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 3,600 participants in total. It began in 2024-06-11 with a primary completion date of 2027-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall goal of the study is to assess the efficacy of using cue exposure delivered via a smartphone application as an adjunct to Tobacco Quitline treatment to improve smoking abstinence.
Eligibility Criteria
Inclusion Criteria: * \>18 years of age * Daily smokers that have quit smoking within the past 3 months (Aim 1) or currently smoking ≥ 3 cigarettes per day for the past year (Aim 2) * Functioning telephone number * Owns a smart phone capable of supporting AR and willing to download the app * Can speak, read and write in English Exclusion Criteria: * Has another household member already enrolled in the study
Contact & Investigator
Christine Vinci, PhD
PRINCIPAL INVESTIGATOR
Moffitt Cancer Center
Frequently Asked Questions
Who can join the NCT06088498 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Smoking. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06088498 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06088498 currently recruiting?
Yes, NCT06088498 is actively recruiting participants. Contact the research team at Christine.Vinci@moffitt.org for enrollment information.
Where is the NCT06088498 trial being conducted?
This trial is being conducted at Tampa, United States.
Who is sponsoring the NCT06088498 clinical trial?
NCT06088498 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Christine Vinci, PhD at Moffitt Cancer Center. The trial plans to enroll 3,600 participants.